Noteworthy, we found that in breast cancer patients TBX3 has many mutations, the majority of which are truncating and missense mutations classified as likely oncogenic and likely loss-of-function events, suggesting that TBX3 acts as a tumor suppressor in breast cancer (Fig. 8F and G). Here, TBX3 is linked to neoplasm.